TY - JOUR
T1 - Amphetamine-induced striatal dopamine release in schizotypal personality disorder
AU - Thompson, Judy L.
AU - Rosell, Daniel R.
AU - Slifstein, Mark
AU - Xu, Xiaoyan
AU - Rothstein, Ethan G.
AU - Modiano, Yosefa A.
AU - Kegeles, Lawrence S.
AU - Koenigsberg, Harold W.
AU - New, Antonia S.
AU - Hazlett, Erin A.
AU - McClure, Margaret M.
AU - Perez-Rodriguez, M. Mercedes
AU - Siever, Larry J.
AU - Abi-Dargham, Anissa
N1 - Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Rationale: Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD. Objectives: To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD. Methods: We used positron emission tomography with [11C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BPND), and its percent change post-amphetamine (∆BPND) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory. Results: There were no significant group differences in BPND or ∆BPND in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BPND in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BPND in several striatal subregions. Conclusions: In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.
AB - Rationale: Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD. Objectives: To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD. Methods: We used positron emission tomography with [11C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BPND), and its percent change post-amphetamine (∆BPND) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory. Results: There were no significant group differences in BPND or ∆BPND in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BPND in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BPND in several striatal subregions. Conclusions: In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.
KW - Disorganized symptoms
KW - Dopamine
KW - PET
KW - Positive symptoms
KW - Schizophrenia
KW - Schizotypal personality disorder
KW - Striatum
KW - Working memory
UR - https://www.scopus.com/pages/publications/85086741762
UR - https://www.scopus.com/pages/publications/85086741762#tab=citedBy
U2 - 10.1007/s00213-020-05561-5
DO - 10.1007/s00213-020-05561-5
M3 - Article
C2 - 32572588
AN - SCOPUS:85086741762
SN - 0033-3158
VL - 237
SP - 2649
EP - 2659
JO - Psychopharmacology
JF - Psychopharmacology
IS - 9
ER -